CorMedix (CRMD) 10-K2021 FY Annual report

Filed: 29 Mar 22, 4:31pm

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. sophomore Avg

New words: accomplish, al, Amgen, Amneal, ASU, Australia, Australian, BA, benchmarking, beneficiary, Carlo, concurrently, covenant, custodian, DEFICIENCY, deliberation, Delta, discretionary, docket, Eckerd, emphasize, feedback, fiduciary, Fordham, Gemini, grandchildren, Gregory, Impax, Inline, involuntary, Joseph, Jr, jurisdiction, lawsuit, Linkbase, Liz, LP, Marsh, McLennan, mix, Monte, motion, necessitated, NGFP, niche, Nihonbashi, Nomura, Nusbickel, Omicron, Opko, Oppenheimer, PAAL, paragraph, Pepperdine, perspective, plaintiff, Plaza, prejudice, purported, Ranbaxy, Recce, refile, rejected, resubmission, resurgence, retired, retirement, role, Schema, spite, statute, stipulation, TauoLock, Taxonomy, tied, Todisco, Tokyo, traceable, Truist, UK, variant, vigorously, Vizient, voluntary, Voter, widespread, withdrew, workplace, xix, xx, xxi, xxii, xxiii, xxiv, xxv, xxvi, xxvii

Removed: accounted, Aeronautical, Africa, allocate, allocation, analyze, argumentation, assistance, biography, biotech, Black, British, BSc, call, categorize, categorized, Chew, clarifying, compare, compounded, conjunction, consented, Correvio, CPIM, Cranfield, Cytogel, disposed, Dow, DuPont, earliest, Eastern, Eli, Endo, Engineering, estimating, exchanged, expiry, explained, feature, firmly, founded, French, Genaera, hundred, hybrid, implicitly, integrated, intent, inventory, judge, Khan, Lilly, London, Marion, Merck, Metaphore, month, NYSE, Oread, outlining, Paul, Poxel, precise, presiding, prioritize, projected, promising, recoverability, reevaluate, region, rescheduled, reserve, retained, retrospective, ruled, secret, Secretary, sector, shipped, spanning, Sr, supplying, traded, Urocor, warehouse, warranty, write

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

Associated CRMD transcripts

CRMD similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.1

CERTIFICATION OF THE PRINCIPAL EXECUTIVE OFFICER AND PRINCIPAL FINANCIAL OFFICER
PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the annual report of CorMedix Inc. (the “Company”) on Form 10-K for the year ended December 31, 2021, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Matthew David, Interim Chief Executive Officer and Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:

(1)

The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

March 29, 2022	/s/ Matthew David
	Name:	Matthew David
	Title:	Interim Chief Executive Officer and Chief Financial Officer
		(Principal Executive Officer)

March 29, 2022	/s/ Matthew David
	Name:	Matthew David
	Title:	Interim Chief Executive Officer and Chief Financial Officer
		(Principal Financial Officer)